Guardant Health AMEA is pleased to be part of the conference delegation in the upcoming World Conference on Lung Cancer, taking place in Barcelona from 7th to 10th September 2019. With the global lung cancer burden standing at approximately 2.1 million new cases in 2018, participating in conferences like this are essential in sustaining our efforts to conquer cancer with data. The following AMEA abstracts have been accepted as poster presentations at WCLC 2019:
– Tumor Mutation Burden through Hybrid Capture – circulating tumor DNA may predict response to Immunotherapy in NSCLC
– Serial plasma ctDNA tests identify genomic alterations for early prediction of osimertinib treatment outcome in T790M+ NSCLC
– Prospective study for usefulness of plasma DNA on prediction of third generation EGFR tyrosine kinase inhibitors (S-PLAT study)